ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 182-188

  Duong, Hong Quan ^a   Kim, Hee Jeong ^a   Kang, Hyo Jin ^a   Seong, Yeon Sun ^b   Bae, Insoo ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

Author keywords

Apoptosis; Gemcitabine; Human pancreatic adenocarcinoma; Phosphatidylinositol 3 kinase akt pathway; ZSTK474

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; CASPASE 3; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; TRIAZINES;

EID: 84855275576     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1503     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Keighley MR: Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 18 (Suppl 3): 7-30, 2003.
3. Bardeesy N and Depinho RA: Pancreatic cancer biology and genetics. Nat Rev Cancer 2: 897-909, 2002. (Pubitemid 37328891)
4. Chua YJ and Zalcberg JR: Pancreatic cancer-is the wall crumbling? Ann Oncol 19: 1224-1230, 2008.
5. Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Berardi R, Bianconi M and Cascinu S: Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol 67: 27-38, 2008.
6. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
7. Ducreux M, Boige V and Malka D: Treatment of advanced pancreatic cancer. Semin Oncol 34: S25-S30, 2007. (Pubitemid 46590362)
8. Ng SSW, Tsao MS, Chow S and Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60: 5451-5455, 2000.
9. Yokoi K and Fidler U: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10: 2299-2309, 2004.
10. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Fala F and Cocco L: Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 18: 1101-1107, 2006. (Pubitemid 43674029)
11. Izuishi K, Kato K, Ogura T, Kinoshita T and Esumi H: Remarkable tolerance of tumor cells to nutrient depravation: possible new biochemical target for cancer therapy. Cancer Res 60: 6201-6207, 2000.
12. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol 3′-kinase-Akt pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997, 2002.
13. Workan P, Clarke PA, Raynaud FI and van Montfort RL: Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70: 2146-2157, 2010.
14. Yaguchi S, Izumisawa Y, Sato M, Nakagane T, Koshimizu I, Sakita K, Kato M, Yoshioka K, Sakato M and Kawashima S: In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives. Biol Pharm Bull 20: 698-700, 1997. (Pubitemid 27300350)
15. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K and Yamori T: Anti-tumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98: 546-556, 2006.
16. Kong D, Dan S, Yamazaki K and Yamori T: Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K super-family and human cancer cell line panel JFCR39. Eur J Cancer 46: 1111-1121, 2010.
17. Dong DX and Yamori T: ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin 31: 1189-1197, 2010.
18. Kong D and Yamori T: ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms. Cancer Sci 98: 1638-1642, 2007. (Pubitemid 47308463)
19. Dan S, Yoshimi H, Okamura M, Mukai Y and Yamori T: Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun 379: 104-109, 2009.
20. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs and enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
21. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bierke LM, Kelland L, Valenti M, Patterson L, Gowan D, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saqhir N, Parker P, Waterfield M and Workman P: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3 kinases. Cancer Res 67: 5840-5850, 2007. (Pubitemid 46985018)
22. Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumad or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717, 2002.
23. Yotsumoto F, Fukami T, agi H, Funakoshi A, Yoshizato T, Kunoki M and Miyamoto S: Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci 101: 2351-2360, 2010.
24. Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T and Suzuki Y: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 27: 76, 2008.
25. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taquchi S, Tsujioka K, Ueno Y. Hatch H, Majumder PK, Pan BS and Kotani H: MK-2206, an allosteric Akt inhibitor, enhances anti-tumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9: 1956-1967, 2010.